SDT involves two primary components: ultrasound and sonosensitizers. Sonosensitizers are non-toxic compounds that, upon ultrasound activation, produce ROS. These ROS can damage cellular structures, leading to the death of cancer cells. The process generally includes the following steps:
Administration of sonosensitizers, which selectively accumulate in cancerous tissues. Application of focused ultrasound waves to the tumor site, activating the sonosensitizers. Generation of ROS, which induce apoptosis or necrosis in cancer cells.
